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OUTLOOK

The power of the few
Ran Chen, Yuan Pan, and David H. Gutmann
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA

“Never in the field of human conflict was so much owed
by so many to so few,” remarked Winston Churchill in
his praise of the contributions of the Allied airmen of
the Royal Air Force during the Second World War. In
keeping with the power of the few, Furnari and colleagues
(Zanca et al. 2017) now report that a small population of
cancer cells in high-grade brain tumors (glioblastoma)
can orchestrate the complex behavior of the entire tumor.
Glioblastomas are deadly malignancies characterized by
significant cellular and molecular heterogeneity. As
such, malignant gliomas are composed of numerous distinct cell types, including various neoplastic cells (glioma
stem cells and neoplastic astrocytes) and nonneoplastic
cells (endothelial cells, reactive astrocytes, and tumor-associated monocytes). Moreover, even among the neoplastic cells, there exists considerable heterogeneity, with
subpopulations of cancer cells exhibiting specific transcriptomal profiles and expressing different mutations
(Patel et al. 2014). One of these signature mutations involves the epidermal growth factor receptor (EGFR), in
which several exons encoding sequences in the extracellular domain of this receptor tyrosine kinase (RTK) are deleted (EGFRvIII mutation), resulting in an aberrantly
functioning hyperactive EGFR molecule. While EGFRvIII
mutant glioblastoma cells comprise only 15% of the total
cancer cells in the tumor, they can serve as critical sculptors of the tumor microcosm.

In this issue of Genes & Development, Zanca et al.
(2017) demonstrate that EGFRvIII mutant glioblastoma
cells control the survival of wild-type (nonmutant)
EGFR-expressing glioblastoma cells as well as provide a
unique escape mechanism for evading therapeutic RTK
inhibition. These studies identified interleukin-6 (IL-6),
secreted by EGFRvIII mutant glioblastoma cells, as an
anti-apoptotic effector responsible for attenuating glioblastoma cell sensitivity to EGFR tyrosine kinase inhibitor (TKI) therapy. IL-6-mediated reduced EGFR TKI
sensitivity has also been reported in non-small cell lung
cancer, where EGFR TKI treatment triggers IL-6-mediated
feedback through activation of Stat3 and downstream prosurvival genes (Lee et al. 2014). However, in glioblastoma,
IL-6 also acts in a paracrine manner and binds to a common IL-6 receptor (gp130) located on wild-type EGFR-expressing glioblastoma cells. gp130 engagement by IL-6
results in NF-kB activation, leading to expression of survivin, an anti-apoptotic protein. In this fashion, survivin induction protects glioblastoma cells from EGFR TKImediated apoptosis by providing an alternative way to
activate the mechanistic target of rapamycin (mTOR)
complex, thus bypassing TKI suppression of mTOR-mediated cell growth. Importantly, mutant EGFRvIII also
increases NFkB activity, resulting in elevated IL-6 transcription. Since NF-κB is responsible for both IL-6 production in EGFRvIII mutant glioblastoma cells and IL-6mediated survivin induction in wild-type EGFR-expressing tumor cells, inhibitors that blocked NF-κB activation
were sufficient to overcome TKI resistance in these brain
cancers.
Collectively, the new findings described in this report
add to an ever-deepening appreciation of how a small
number of cells in any given tumor can dictate the biological behavior of the entire cancer as well as how the glioblastoma ecosystem is maintained through intersecting
activities mediated by one particular subpopulation of
driver cells. The notion that an “Achilles’ heel” cell
type exists in glioblastoma is exciting given the relative
resistance of these cancers to conventional and investigational therapies. However, the dark side of this notion is
that numerous different cancer cell types could evolve
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Converging evidence from numerous laboratories has revealed that malignant brain cancers are complex ecological systems composed of distinct cellular and acellular
elements that collectively dictate glioblastoma biology.
Our understanding of the individual contributions of
each of these components is vital to the design of effective
therapies against these cancers. In this issue of Genes &
Development, Zanca and colleagues (pp. 1212–1227) demonstrate that one subpopulation of glioblastoma cells
expressing a mutant epidermal growth factor receptor
(EGFRvIII) is responsible for the survival of non-EGFRvIII-expressing tumor cells as well as for evading molecularly targeted therapy.
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Figure 1. EGFRvIII is a master regulator of
glioblastoma ecosystem biology. EGFRvIII
mutation in a small population of glioblastoma
cells can have profound effects on numerous
distinct cell types and thus influence the biology of the entire tumor. First, EGFRvIII expression leads to EGFR activation and the
engagement of downstream signaling pathways and transcriptional programs, leading to
increased cell growth by either driving cell cycle progression or limiting programmed cell
death. Second, EGFRvIII expression can indirectly promote cell expansion through the
elaboration of cytokines (e.g., IL-8 and VEGF)
that engage tumor-associated monocytes
(TAMs) or endothelial cells (angiogenesis), resulting in the elaboration of glioma-promoting
growth factors (gliomagens). Third, EGFRvIII
expression can increase glioma cell growth
via aberrant expression or transactivation of
other RTKs (e.g., c-MET). Fourth, EGFRvIII expression can lead to the production of other
growth factors (e.g., heparin-binding EGF [HBEGF] and TGF-α), which can increase the
growth of other glioblastoma cells in the tumor
through activation of the wild-type EGFR. Last, EGFRvIII expression can trigger elevated levels of IL-6, which promotes cell survival by
binding to the IL-6 receptor (gp130).

within the tumor biome to influence overall glioblastoma
growth, thus creating opportunities to escape future designer chemotherapies.
As a case in point, mutant EGFR expression in a small
population of cancer cells can lead to profound changes
in the glioblastoma ecosystem through a variety of distinct, nonmutually exclusive mechanisms (Fig. 1). First,
EGFRvIII has the capacity to transactivate other RTKs
and, in doing so, drive tumor growth or limit therapeutic
responses (Huang et al. 2007; Pillay et al. 2009). For example, EGFRvIII transactivation of the hepatocyte growth
factor (HGF) receptor (MET) leads to resistance to rilotumumab, an antibody therapy that blocks tumor growth
by neutralizing HGF and inhibiting HGF-mediated MET
signaling (Pillay et al. 2009). Similarly, EGFRvIII receptors
can increase the activation of other RTKs through their inappropriate retention at the cell surface (Greenall et al.
2015) or by forming heterodimers that cause aberrant
RTK activation and increased mitogenic signaling (Greenall et al. 2015).
Second, EGFRvIII expression can directly control the
growth of other tumor cells in the glioma as a consequence of paracrine secretion of cytokines and growth factors. In addition to IL-6 regulation of glioblastoma cell
growth via gp130 receptor-mediated induction of survivin, EGFRvIII-expressing glioblastoma cells produce other
EGFR ligands, such as heparin-binding EGF (HB-EGF) and
TGF-α (Ramnarain et al. 2006), each of which can act on
the wild-type EGFR receptor to drive tumor cell growth.
Similarly, EGFR mutant glioblastoma cells increase IL-8
production, which additionally enhances glioblastoma
stem cell growth. Moreover, chemokines (such as CCL5,
secreted by glioblastoma cells) can create autocrine
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growth-promoting circuits in which tumor cells produce
their own mitogens in a self-stimulating manner to promote cell survival (Pan et al. 2017).
Third, cytokines and chemokines induced by mutant
EGFR expression can alter the glioblastoma microenvironment through the recruitment or activation of stromal
cell types, such as endothelial cells and monocytes (macrophages and microglia). For example, mutant EGFR induces IL-8 and vascular endothelial growth factor
(VEGF) secretion to increase angiogenesis in human glioblastoma xenografts (Infanger et al. 2013). In addition,
monocytes are recruited by chemokines (e.g., CX3CL1,
CCL5, and CCL2) produced by glioblastoma cells. These
tumor-associated microglia or macrophages are induced
to secrete IL-6, EGF, and likely other mitogens to establish
paracrine relationships that further enhance glioblastoma
growth (Zhang et al. 2012).
Taken together, the findings reported by Zanca et al.
(2017) provide a conceptual framework in which the collective behavior of the tumor is defined by the adaptive
mechanisms and circuits initiated and orchestrated by a
small population of tumor cells. With a greater understanding of these interconnections, future therapies might
emerge that target these bionetworks at multiple nodes of
vulnerability.
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